Johnson & Johnson (NYSE: JNJ) today announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies designed to deliver superior comfort and visual clarity, even at day 14. The lens will be rolled out in select European countries later this year with wider market rollout in 2027.
Globally, 140 million people wear contact lenses, with one in two choosing a reusable lens, and comfort remains their leading priority. With the continued rise in everyday use of digital devices and exposure to blue-violet light, more demands are being placed on patients’ eyes, often leading to reduced visual clarity and symptoms of dryness.
ACUVUE OASYS MAX 2-Week brings Johnson & Johnson’s advanced MAX contact lens technologies to reusable contact lens wearers, helping address their evolving vision, comfort, and digital lifestyle needs.
“People who choose reusable contact lenses should not have to compromise on comfort or clarity as their days get busier and their eyes work harder,” said Jacqueline Henderson, Company Group Chair, Vision, MedTech, Johnson & Johnson.
“With ACUVUE OASYS MAX 2-Week, we are bringing our most advanced ACUVUE technologies to a reusable lens, helping more people see clearly and feel comfortable throughout the full two-week wear cycle.”
JNJ shares improved 26 cents to $267.33.
